Invasive breast cancer (IBC) evolves through a series of increasingly abnormal premalignant stages, over decades in most cases [1, 2] . Ductal carcinoma in situ (DCIS) is a late stage in this evolution and the immediate precursor for most IBC. Currently, about 60,000 new cases of DCIS are diagnosed in the USA each year [3] . If undetected, at least one-third of cases will progress to IBC [4] . About 200,000 cases of IBC are also diagnosed [3] , and nearly all evolve from DCIS that was not detected.
con sis tent with previous studies showing that FGFR1 activation is oncogenic for breast cancer in transgenic mice [9] , and is associated with increased invasion of breast cancer cell lines in vitro [10] and poor prognosis in IBC [7, 11, 12] , especially in receptor-positive disease [11, 12] .
Although our understanding of FGFR1 at the molecular level is incomplete, important aspects are known about its function and the consequences of gene amplifi cation [13] . For example, the gene encodes a tyrosine kinase receptor that is part of a large family of fi broblast growth factors and receptors. In a normal setting, activation of FGFR1 can lead to transactivation of mitogen-activated protein kinase and AKT, which collectively are essential for breast development, including the growth and diff erentiation of luminal epithelial cells. However, increased FGFR1 activity, such as occurs through gene amplifi cation, can result in increased luminal cell prolifera tion and, in transgenic mouse models, this hyperplasia may eventually evolve into in situ and invasive mammary carcinomas.
In humans, the chromosomal region where FGFR1 resides, 8p11.2, is amplifi ed in signifi cant proportions of many types of cancers, including kidney cancer, lung cancer, prostate cancer, and leukemias. Th e region is also amplifi ed in 10 to 20% of IBC [13] . However, the 8p11.2 amplicon is large and complex, and FGFR1 is only one of several candidate oncogenes within the region [14] others include LSM1, PPAPDC1B, WHSC1L1, and BAG4, which are also important in breast development and cell cycle regulation, among other relevant functions. To complicate matters more, only about 50% of FGFR1-amplifi ed tumors appear to overexpress the transcript [15] .
Th e study by Jang and colleagues provides additional evidence of an important role for FGFR1 amplifi cation in the progression of IBC [1] . Th e study also provides tantalizing hints that FGFR1 may be important in the in situ to invasive transition, which is a critical step in the progression of a nonlethal to potentially lethal diseaseand this aspect of the study is entirely novel. Having said this, we need to be cautious about drawing conclusions regarding gene function and malfunction based on correlative studies of this nature alone. For example, the main evidence that FGFR1 is important in this study is elevated amplifi cation in IBC versus DCIS. By analogous reasoning, the elevated amplifi cation of HER2 observed in DCIS versus IBC could be taken as evidence for suppression of tumor progression, which we know is wrong. Determining the molecular function, oncogenic potential, and clinical signifi cance of FGFR1 at any stage of breast cancer evolution will require many additional comprehensive laboratory and clinical studies. Th ese studies are particularly worthwhile in the sense that we have eff ective drugs to inhibit FGFR1 activity [13] . Jain and Turner have summarized recent interesting data in terms of the functional biology of the fi broblast growth factor receptors and development of inhibitors of these molecules, with emphasis on challenges to successfully target this pathway in breast cancer [16] . Th ese could lead to new strategies for preventing the progression of DCIS to IBC, or restoring responsiveness of receptorpositive IBC to endocrine therapy if activation is confi rmed to induce resistance [11, 12] -perhaps FGFR1 will be the next HER2.
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